Clinical and demographic characteristics of the cohort of patients categorised according to cancer status
| Variable | No SigPCa n=423 | SigPCa n=87 | All n=510 |
| Age | 64.0 (60.0–69.0) | 68.0 (63.0–71.0) | 65.0 (60.0–70.0) |
| Family history | 81 (19.1) | 8 (9.2) | 89 (17.5) |
| Positive DRE | 55 (13.0) | 27 (31.0) | 82 (16.1) |
| 1 serum PSA | 5.3 (4.3–6.9) | 5.8 (4.5–7.2) | 5.3 (4.3–6.9) |
| 1 free PSA % | 16.2 (12.4–21.4) | 12.5 (9–16.6) | 15.9 (11.8–20.4) |
| 2 serum PSA | 5.0 (3.7–6.6) | 5.4 (4.1–6.7) | 5.0 (3.8–6.6) |
| 2 free PSA % | 17.9 (13.9–23.4) | 12.5 (9.1–16.3) | 16.9 (12.8–22.1) |
| Prostate volume | 38.0 (29.0–50.0) | 26.0 (20.7–34.0) | 35 (26–49) |
| First biopsy | 322 (76.1) | 79 (90.8) | 401 (78.6) |
| PCPT1 SigPCa | 0.08 (0.05–0.13) | 0.16 (0.10–0.30) | 0.09 (0.06–0.15) |
| ERSPC1 SigPCa | 0.05 (0.02–0.10) | 0.12 (0.05–0.31) | 0.05 (0.03–0.12) |
| PCPT2 SigPCa | 0.07 (0.04–0.11) | 0.16 (0.08–0.27) | 0.07 (0.05–0.13) |
| ERSPC2 SigPCa | 0.04 (0.02–0.08) | 0.12 (0.05–0.30) | 0.05 (0.02–0.11) |
| PCa | 89 (21) | 87 (100) | 176 (34.5) |
Median values (IQR) are expressed for quantitative variables and absolute values (percentage) for qualitative variables.
DRE, digital rectal examination; ERSPC1/PCPT1 SigPCa, probability of high-grade PCa using the first measurement of serum PSA (at the time of biopsy indication by the urologist); ERSPC2/PCPT2 SigPCa, probability of high-grade PCa using the second measurement of serum PSA (just before undergoing prostate biopsy); No SigPCa, no cancer or non-significant PCa; PCa, prostate cancer; PSA, prostate-specific antigen; SigPCa, significant PCa (Gleason ≥7 on biopsy).